Related Experiment Video
Updated: Nov 9, 2025

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
Genetic justification of severe COVID-19 using a rigorous algorithm
Eleni Gavriilaki1, Panagiotis G Asteris2, Tasoula Touloumenidou1
1Hematology Department - BMT Unit, G Papanicolaou Hospital, Thessaloniki, Greece.
Insights
Genetic factors like ADAMTS13, C3, and CFH variants are linked to severe COVID-19 and ICU admission. Identifying these genetic susceptibilities may guide targeted treatments for high-risk patients.
Area of Science:
- Immunogenetics
- Infectious Diseases
- Hematology
Background:
- Severe COVID-19 (coronavirus disease 19) involves excessive complement system activation, similar to complement-mediated thrombotic microangiopathy (TMA).
- Genetic predisposition may influence COVID-19 severity, mirroring patterns observed in TMA.
Purpose of the Study:
- To investigate genetic susceptibility in severe COVID-19 patients.
- To determine if genetic variants are associated with disease severity, specifically ICU hospitalization.
Main Methods:
- Analysis of genetic and clinical data from 97 hospitalized COVID-19 patients.
- Targeted next-generation sequencing to identify variants in ADAMTS13, C3, and complement factor H (CFH).
Main Results:
- ADAMTS13 variants were found in 49 patients; C3 variants in 21, and CFH variants in 34.
- A combination of these variants was independently associated with ICU hospitalization (p=0.022).
- Specific combinations, like rs1042580 (thrombomodulin) with absence of rs800292 (CFH), correlated with no ICU need.
Conclusions:
- Genetic variations in complement-related genes and ADAMTS13 are associated with severe COVID-19 and ICU admission.
- This highlights a potential patient subgroup that could benefit from early complement inhibitor therapy.
- Observed gender differences in variant distribution warrant further investigation.
Abstract:
Recent studies suggest excessive complement activation in severe coronavirus disease-19 (COVID-19). The latter shares common characteristics with complement-mediated thrombotic microangiopathy (TMA). We hypothesized that genetic susceptibility would be evident in patients with severe COVID-19 (similar to TMA) and associated with disease severity. We analyzed genetic and clinical data from 97 patients hospitalized for COVID-19. Through targeted next-generation-sequencing we found an ADAMTS13 variant in 49 patients, along with two risk factor variants (C3, 21 patients; CFH,34 patients). 31 (32%) patients had a combination of these, which was independently associated with ICU hospitalization (p = 0.022). Analysis of almost infinite variant combinations showed that patients with rs1042580 in thrombomodulin and without rs800292 in complement factor H did not require ICU hospitalization. We also observed gender differences in ADAMTS13 and complement-related variants. In light of encouraging results by complement inhibitors, our study highlights a patient population that might benefit from early initiation of specific treatment.
Related Concept Videos
Single Nucleotide Polymorphisms-SNPs
Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
What is Genetic Engineering?
Genetic Variation
Genes exist in different versions called alleles,...
CRISPR
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...

